Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Novo’s troubled Indiana plant claims another victim as FDA rejects Incyte’s lung cancer application
Latest from Blog
Protein alone is not enough: This is the missing piece of nutrition for your peak health
If you are on a high protein diet, consuming carbs becomes even more essential. Here’s why. Post Views: 1
Catholic organizations call on Congress to protect food aid, nutrition programs
The appeal comes as Pope Leo XIV dedicated his May prayer intention to ensuring “that everyone might have food.” Post Views: 1
Cherokee Nation expanding hours for Nowata and Stilwell elder nutrition sites
The Cherokee Nation said they will be expanding the operations for their Nowata and Stilwell elder nutrition sites to five days a week. Post Views: 1
Local author’s book ‘Drug-Free Crohn’s’ highlights healing journey by nutrition, fitness, faith
For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease. Post Views: 1
Elder Nutrition sites expand hours; nutrition efforts enhanced
The Cherokee Nation recently announced its elder nutrition sites in Nowata and Stilwell will be open five days a week, providing nutritious meals and a place to gather and fellowship Post Views: